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An abluminal biodegradable 
polymer sirolimus-eluting 
stent versus a durable polymer 
everolimus-eluting stent in 
patients undergoing coronary 
revascularization: 3-year clinical 
outcomes of a randomized non-
inferiority trial
Haijun Zhang1,2,3,7, Xiaoping Zhang  1,7*, Yuxia Yin3, Chao Zhou3, Wei Deng4, Junwei Zhang3, 
Wenbo Hou3, Shoutao Lu3, Caixia Song3, Xiaoshan cui3, Shenguo Wang5, Fei Yang5, 
Guang Liu3, Cuihai Duan3 & Junbo Ge  6*
The Cordimax stent has proved non-inferior to the Cypher Select durable polymer sirolimus-eluting 
stent for the primary endpoint of angiographic in-stent late luminal loss and in-stent mean diameter 
stenosis at 9 months. The trial was designed to compare the efficacy and safety of the Cordimax 
stent with the Xience V stent in patients undergoing coronary revascularization. This randomized, 
multicenter trial enrolled 3697 patients treated with Cordimax stent (2460 patients) and Xience V stent 
(1237 patients). The primary efficacy endpoint was a target-lesion failure (TLF) at 1 year and the primary 
safety endpoint was a composite of death or myocardial infarction (MI) at 3 years. 3399 patients (91.9%) 
completed 3-year follow-up. At 1 year, the primary efficacy endpoint occurred in 86 (3.5%) patients 
in the Cordimax group versus 40 (3.2%) patients in the Xience V group (0.3% absolute risk difference, 
95% CI −1.0–1.5%, Pnon-inferiority < 0.0001). At 3 years, the primary safety endpoint occurred in 39 (1.6%) 
patients in the Cordimax group versus 19 (1.5%) patients in the Xience V group (0.05% absolute risk 
difference, 95% CI −0.8–0.9%, Pnon-inferiority < 0.0001). The incidence of target lesion revascularization 
was low in Cordimax group compared with Xience V group (3.6% versus 5.1%, P = 0.03). There were 
no differences between Cordimax and Xience V in terms of Cardiac death (0.3% versus 0.4%, P = 0.70), 
myocardial infarction (1.2% versus 0.9%, P = 0.37), and the stent thrombosis (0.4% versus 0.6%, 
P = 0.61). In conclusion, safety and efficacy outcomes of Cordimax stent were non-inferior to the Xience 
V stent 3 years after stent implantation.
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Drug-eluting stents (DES) with controlled release of antiproliferative agents from a durable polymer have effec-
tively reduced the incidence of restenosis and major cardiac events including myocardial infarction (MI) and 
cardiac death compared with bare-metal stents (BMS)1,2. However, first generation durable polymer DES have 
been linked to increased risk of stent thrombosis (ST), especially very late ST (VLST) after discontinuation of 
dual antiplatelet therapy3,4. The durable polymer matrix has been implicated as a likely trigger of delayed reen-
dothelialization and chronic inflammation leading to these late complications5,6. The introduction of newer DES 
of improved durable polymers or biodegradable polymers has significantly reduced the risk of cardiac complica-
tions after stent implantation7. Cordimax (Rientech Medical, Shandong, China) is a novel biodegradable polymer 
sirolimus-eluting stent with an asymmetric coating, eluting the drug solely to the abluminal surface. Compared 
with a stent with conventional coating, Cordimax has demonstrated favorable drug release profile in vitro and in 
vivo8 and afforded enhanced endothelialization and vascular healing after implantation in vivo9. In our previous 
randomized clinical trial comparing the safety and efficacy of Cordimax and Cypher Select (Cordis®, Miami 
Lakes, FL, USA), a durable polymer sirolimus-eluting stent, Cordimax demonstrated non-inferiority to Cypher 
Select at 9-month angiographic and 1-year clinical follow-up10. Cypher was the first-generation drug eluting stent 
(DES) which has a non-degradable coating and is made of 316 L stainless steel, which suppresses the occurrence 
of restenosis associated with bare metal stents (BMS)11,12. However, due to the high incidence of very late stent 
thrombosis its secure usage had been challenged13,14. Xience V (Abbott Vascular, Santa Clara, CA, USA) is the 
newer generation DES which is made of thinner stent and its safety and effectiveness has been demonstrated in 
multiple clinical trials15. The incidence of thrombosis using Xience V had been observed to be significantly lower 
than the Cypher16. Therefore, the aim of this clinical trial was to evaluate the safety and efficacy of Cordimax com-
pared with Xience V, a durable polymer everolimus-eluting stent, at 3-year clinical follow-up.
Results
A total of 3697 patients with 4281 lesions were randomly assigned to receive either the Cordimax biode-
gradable polymer sirolimus-eluting stent (2460 patients with 2866 lesions) or the Xience V durable polymer 
everolimus-eluting stent (1237 patients with 1415 lesions; Fig. 1) in a 2:1 allocation. The baseline demographics 
and the clinical and angiographic characteristics of patients in the two treatment arms were well balanced except 
for CCS (Canadian Cardiovascular Society)/Braundward angina pectoris class, and NYHA (New York Heart 
Association) functional class (Table 1). Higher proportions of patients in the Cordimax arm had angina class IV 
(10.7% of Cordimax vs. 6.9% of Xience V) and NYHA class III or IV (21.9% and 1.5% of Cordimax vs. 14.8% 
and 0.6% of Xience V) (Table 1). The total stent length per patient was slightly shorter in the Cordimax group 
(25.00 mm Cordimax vs. 25.99 mm Xience V, P = 0.20; Table 1). A total of 3399 patients (91.9%; 2272 in the 
Cordimax arm and 1127 in the Xience V arm) completed 3-year follow-up (Fig. 1).
At 1 year, the primary efficacy endpoint (TLF) occurred in 86 (3.5%) patients in the Cordimax group versus 
40 (3.2%) patients in the Xience V group (Table 2, Fig. 2). With an absolute risk difference of 0.3% and the upper 
limit of the two-sided 95% CI at 1.5% (95% CI −1.0–1.5%), the Cordimax stent proved to be non-inferior to 
the Xience V stent at 1 year after implantation (Pnon-inferiority < 0.0001). At 3 years, the primary efficacy endpoint 
(TLF) occurred in 121 (4.9%) patients in the Cordimax group versus 78 (6.3%) patients in the Xience V group 
(Table 2, Fig. 2). Non-inferiority of the Cordimax stent at 3 years was established with an absolute risk difference 
of −1.39% and the upper limit of the two-sided 95% CI at 0.2% (95% CI −3.0–0.2%, Pnon-inferiority = 0.0242). With 
regard to the secondary clinical safety and efficacy endpoints, target lesion revascularization (3.6% versus 5.1%, 
Figure 1. Trial profile. Enrollment and Randomization of Patients Who underwent coronary revascularization.
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P = 0.03) were less frequent among Cordimax-treated patients compared with Xience V-treated patients. There 
were no differences between Cordimax and Xience V in terms of Cardiac death (0.3% versus 0.4%, P = 0.70), 
myocardial infarction (1.2% versus 0.9%, P = 0.37), and the definite or probable stent thrombosis (0.4% versus 
0.6%, P = 0.61) at 3 years. At 3 years, the primary safety endpoint occurred in 39 (1.6%) patients in the Cordimax 
group versus 19 (1.5%) patients in the Xience V group (Table 2, Fig. 2). With an absolute risk difference of 0.05% 
and the upper limit of the two-sided 95% CI at 0.9% (95% CI −0.8–0.9%, Pnon-inferiority < 0.0001) demonstrating 
noninferiority of Cordimax stent relative to Xience V stent.
Between 1 and 2 years, the rates of the primary efficacy endpoint and the primary safety endpoint were similar 
in both groups. Rates of the combined and other individual components of the secondary endpoint between 1 and 
2 years did not differ significantly between the two stent groups (Table 3). Between 2 and 3 years, lower portions 
of patients in the Cordimax group had TLF (0.3% versus 1.4%, P < 0.001), TLR (0.2% versus 1.1%, P < 0.001), 
and MACE (0.3% versus 1.4%, P < 0.001). The primary safety endpoint, and other individual components of the 
secondary endpoints did not differ significantly between the two stent groups (Table 4). At 3 years, the cumulative 
incidence of Definite or Probable Stent Thrombosis was not different between the 2 groups (0.4% versus 0.6%, 
P = 0.61; Table 5).
Univariate and multivariate analysis show that the location of the target lesion was an independent predictor 
of TLF following either Cordimax or Xience V implantation in patients (Table 6). Compared with the patients 
who developed lesions in other parts, patients with left main artery lesions exhibit a higher risk of the occurrence 
of TLF.
Discussion
The main purpose of this present work is to verify the efficacy and safety of the novel biodegradable polymer with 
an asymmetric coating, sirolimus-eluting stent (Cordimax) in relation to its long-term efficacy. Previously, Xience 
V stent from Abbott has been identified to be superior to the first-generation DES which, together with other 
favorable data, led to its approval by regulatory bodies17. Currently, clinical trials use Xience V as control group 
for their non-inferiority clinical trials18. Hence, the aim of the present study is to investigate the non-inferiority 
Characteristic Cordimax Xience V P value
Number of patients 2460 1237
Age, y 60.74 ± 10.74 60.08 ± 10.67 0.39
Male gender 1749 (71.1%) 923 (74.6%) 0.02
Cardiovascular risk factors
   Diabetes mellitus 480 (19.5%) 240 (19.4%) 0.94
   Hypertension 1369 (55.7%) 741 (59.9%) 0.01
   Current smoker 870 (35.4%) 451 (36.5%) 0.51
Past medical history
   Previous MI 385 (15.7%) 143 (11.6%) 0.001
   Previous Stroke 86 (3.5%) 23 (1.9%) 0.01
   Previous PCI 197 (8.0%) 76 (6.1%) 0.04
   Previous CABG 12 (0.5%) 4 (0.3%)  0.47
CCS/Braunwald < 0.0001
   I 331 (13.5%) 200 (16.2%)
   II 994 (40.4%) 562 (45.4%)
   III 851 (34.6%) 384 (31.0%)
   IV 263 (10.7%) 85 (6.9%)
NYHA <0.0001
   I 876 (35.6%) 454 (36.7%)
   II 982 (39.9%) 581 (47.0%)
   III 538 (21.9%) 183 (14.8%)
   IV 38 (1.5%) 8 (0.6%)
Number of lesions 2866 1415
   Treated lesions per patient 1.17 ± 0.46 1.14 ± 0.41 0.50
   Stents per patient 1.26 ± 0.55 1.22 ± 0.50 0.39
   Stent length per patient, mm 25.00 ± 10.78 25.99 ± 10.68 0.20
Location of target lesion 0.04
   Left anterior descending coronary 1543 (62.7%) 761 (61.5%)
   Left circumflex coronary artery 490 (19.9%) 286 (23.1%)
   Right coronary artery 768 (31.2%) 337 (27.2%)
   Left main artery 65 (2.6%) 31 (2.5%)
Table 1. Baseline Patient and Lesion Characteristics. Values are presented as mean ± SD or n (%) for categorical 
variables.
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of clinical outcomes after implantation of the Cordimax stent when compared with the Xience V stent in patients 
undergoing coronary revascularization. This head-to-head comparison showed non-inferiority of the Cordimax 
biodegradable polymer sirolimus-eluting stent to the Xience V durable polymer everolimus-eluting stent in terms 
of both efficacy and safety. The cumulative rates for TLF at 1, 2 and 3 years were comparable for patients in the 
Cordimax and Xience V groups. However, the cumulative rate for TLF from 1 to 3 years in the Cordimax group 
was lower than that in the Xience V group (1.5% versus 3.1%, P < 0.001, respectively). These data hinted the ten-
dency of the Cordimax stent to outperform the Xience V stent in long-term clinical benefits.
The rates for TLR in the Cordimax groups were low: 2.3% at 1 year and 3.6% at 3 years. These low rates 
were consistent with those reported in our previous trial on Cordimax10. In that randomized controlled trial the 
Cordimax stent proved to be non-inferior to the Cypher Select durable polymer sirolimus-eluting stent (Cordis 
Corporation, NJ, USA) for angiographic in-stent late luminal loss (LLL) at 9 month and MACE at 1year. The rates 
for CI-TLR for the Cordimax stent were 1.5% at 1 year and 3.0% at 5 years10. There was no definite and probable 
stent thrombosis (as defined by ARC criteria) in the Cordimax group while one case of definite very late stent 
thrombosis was seen in the Cypher Select group10. The cumulative rates for MACE, target vessel revasculariza-
tion (TVR), cardiac death and MI at 1 and 5 years were comparable for the Cordimax and Cypher Select stents. 
However, the cumulative rates for MACE and TVR from 2 to 5 years in the Cordimax group were lower than 
those in the Cypher Select group10. Similar to present findings, these results implied the long-term clinical bene-
fits of the Cordimax stent.
Meta-analyses reveal that new-generation DES are associated with lower rates of restenosis, stent thrombosis, 
and mortality compared with first-generation DES19,20. Xience V, a new-generation durable polymer everolimus‐
eluting stent, was identified as being one of the most effective stents in reducing TVR/TLR19. In the RESOLUTE 
All Comers trial, ischemia driven TLR occurred in 5.1% of Xience V patients at 2 years21. This rate was numeri-
cally lower than the 2-year rates reported for the Taxus (5.9%)22, BioMatrix (6.3%)23 and Resolute (5.7%)21 stents. 
The clinical safety and efficacy of the Xience V stent were evaluated in the SPIRIT family of trials. In the larger 
Events Cordimax (n = 2460) Xience V (n = 1237) RR (95% CI) P value
Events at 6 month
   TLF 4 (0.2%) 4 (0.3%) 0.50 (0.13–2.01) 0.32
   All cause death 0 (0%) 1 (0.1%) — —
   Cardiac death 0 (0%) 1 (0.1%) — —
   MI 0 (0%) 0 (0%) — —
   TLR (clinically driven) 4 (0.2%) 3 (0.2%) 0.67 (0.15–2.99) 0.60
   Death or MI 0 (0%) 1 (0.1%) — —
   MACE 4 (0.2%) 4 (0.3%) 0.50 (0.13–2.01) 0.32
Events at 1 year
   TLF 86 (3.5%) 40 (3.2%) 1.07 (0.74–1.55) 0.73
   All cause death 7 (0.3%) 4 (0.3%) 0.88 (0.26–3.00) 0.84
   Cardiac death 6 (0.2%) 3 (0.2%) 1.01 (0.25–4.01) 0.99
   MI 27 (1.1%) 8 (0.6%) 1.70 (0.77–3.72) 0.18
   TLR (clinically driven) 57 (2.3%) 28 (2.3%) 1.02 (0.66–1.60) 0.92
   Death or MI 34 (1.4%) 12 (1.0%) 1.43 (0.74–2.74) 0.29
   MACE 86 (3.5%) 40 (3.2%) 1.08 (0.75–1.56) 0.68
Events at 2 year
   TLF 113 (4.6%) 61 (4.9%) 0.93 (0.69–1.26) 0.65
   All cause death 7 (0.3%) 6 (0.5%) 0.59 (0.20–1.74) 0.33
   Cardiac death 6 (0.2%) 3 (0.2%) 1.01 (0.25–4.01) 0.99
   MI 30 (1.2%) 9 (0.7%) 1.68 (0.80–3.52) 0.17
   TLR (clinically driven) 82 (3.3%) 49 (4.0%) 0.84 (0.60–1.19) 0.33
   Death or MI 37 (1.5%) 115 (1.2%) 1.24 (0.68–2.25) 0.48
   MACE 114 (4.6%) 62 (5.0%) 0.93 (0.68–1.25) 0.61
Events at 3 year
   TLF 121 (4.9%) 78 (6.3%) 0.78 (0.59–1.03) 0.08
   All cause death 9 (0.4%) 8 (0.6%) 0.57 (0.22–1.46) 0.23
   Cardiac death 8 (0.3%) 5 (0.4%) 0.81 (0.26–2.45) 0.70
   MI 30 (1.2%) 11 (0.9%) 1.37 (0.69–2.73) 0.37
   TLR (clinically driven) 88 (3.6%) 63 (5.1%) 0.70 (0.51–0.96) 0.03
   Death or MI 39 (1.6%) 19 (1.5%) 1.03 (0.60–1.78) 0.91
   MACE 122 (5.0%) 79 (6.4%) 0.78 (0.59–1.02) 0.07
Table 2. Cumulative Clinical Events. Values are n (%). *Relative risk (RR) and p values are from the chi-square 
test. MACE, Major Adverse Cardiovascular Event; MI, Myocardial Infarction; TLF, Target Lesion Failure; TLR, 
Target Lesion Revascularisation; and ST, Stent Thrombosis.
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SPIRIT III trial (n = 1,002), treatment with Xience V, as compared with Taxus, resulted in a significant 32% 
reduction in TVF (10.7% versus 15.4%, P = 0.04) and a 45% reduction in MACE (cardiac death, MI, or TLR; 
7.3% versus 12.8%, P = 0.004) at a 2-year follow up24. The SPIRIT V trial for Xience V enrolled 2,700 patients with 
multiple de novo coronary artery lesions at 93 centers in Europe, Asia Pacific, Canada, and South Africa25. In this 
trial, MACE (all death, MI, and TLR) occurred in 2.7% of patients at 30 days. The rates of TLR and definite/prob-
able stent thrombosis at 1 year were 1.8% and 0.66%, respectively. These data demonstrated the excellent safety 
and efficacy of the Xience V stent in a “real‐world” patient population. In the present study, low rates of TLF and 
MACE were observed in both Cordimax group and Xience V group, may associates with advances in coronary 
stent technology, and the inclusion of patients with the less complex coronary lesions. In addition, univariate and 
multivariate analysis show that the location of the target lesion was an independent predictor for TLF, patients 
with left main artery lesions exhibited higher rates of TLF, may associates with artery pressures caused by blood 
flow.
The continued presence of residual polymer after drug elution may cause chronic inflammation of the vessel 
wall, which is considered a potential trigger of stent thrombosis. This has motivated the development of DES 
with biodegradable polymers. Early randomized controlled trials showed that patients treated with biodegrad-
able polymer stents had lower rates of stent thrombosis and subsequent TVR procedures than controls treated 
with first-generation DES26. However, the vast majority of trials comparing biodegradable polymer DES with 
new-generation durable polymer DES have only established non-inferiority. The Nobori® (Terumo, Japan) stents 
are biolimus-eluting stents with biodegradable polymer polylactic acid applied solely to the abluminal surface. 
In the NEXT trial27, the Nobori® biodegradable polymer biolimus-eluting stent showed non-inferiority but not 
superiority to the Xience V stents in terms of the primary efficacy endpoint of TLR at 1 year (4.2% versus 4.2%; 
P for non-inferiority < 0.0001; P for superiority = 0.93). In addition, the rate of definite stent thrombosis was low 
and comparable between the two groups (0.25% vs. 0.06%, P = 0.18).
The stent design, polymer coatings and the antiproliferative drug and its release kinetics have been implicated 
as mechanisms for delayed endothelial healing and chronic inflammation leading to stent thrombosis5,6,28,29. The 
Cordimax stent has a 316 L stainless steel platform, which is the gold standard material with a superior safety pro-
file for stent application. Compared with a cobalt-based alloy, the 316 L stainless steel exhibits a much higher elas-
ticity that allows better stent adhesion and helps reduce vascular damage at the site of implantation. Structurally, 
the Cordimax stent has a special “snap-fastener” design, in which the wave rod is connected with the S rod. This 
feature renders the Cordimax stent superior fatigue resistance. The Cordimax stent is coated solely at the ablumi-
nal stent site with polylactide-co-polyglycolide copolymer, which degrades into carbon dioxide and water after 
sirolimus is released9. Compared with conventionally coated stents, stents coated solely at the abluminal site tend 
to show reduced vascular restenosis and lower incidence of late stent thrombosis9,10. In addition, patented asym-
metric coating and drug loading techniques are employed in the manufacture of the Cordimax stent to ensure 
favorable drug release8 and rapid vascular healing9. The better long-term outcomes seen with the Cordimax stent 
in this trial were in alignment with previous reports evaluating biodegradable polymer DES versus durable pol-
ymer DES26.
Study Limitations
In this trial, the rates of TLF and MACE were low in both groups. This may be related to the inclusion of patients 
with relatively simple lesions (1–2 in situ coronary stenosis). Another limitation of this study was that we did not 
employ optical coherence tomography (OCT) or another imaging catheter to monitor the vascular wall condition 
at 1 month, 3 months and 6 months after the surgery. Finally, this study was limited to 3-year clinical follow-up. 
Ideally, 5-year follow-up results should be reported for a randomized trial of drug-eluting stents30.
conclusions
This study demonstrated non-inferiority of the Cordimax biodegradable polymer sirolimus-eluting stent to the 
Xience V durable polymer everolimus-eluting stent in terms of both efficacy and safety at 3 years.
Methods
Study design and patients. The study was a randomized, open-label, multicenter, non-inferiority trial. 
Patients older than 18 years of age who presented with symptomatic coronary artery disease or evidence of myo-
cardial ischemia, 1–2 in situ coronary lesions, and at least one coronary lesion with ≥50% de novo stenosis in a 
vessel with a diameter of 2.5–4.0 mm between June, 2013 and May, 2014 were eligible for enrollment. The major 
exclusion criteria included a life expectancy of less than a year; pregnancy, known intolerance to the investiga-
tional device or concomitant medications (e.g., anticoagulants or antiplatelet drugs), anticipated discontinua-
tion of dual antiplatelet therapy within the first 6 months, participation or anticipated participation in another 
clinical trial within 3 years, and uncertainty about the completion of 3-year follow-up. The trial was approved by 
the institutional ethics committee of Fudan University Affiliated Zhongshan Hospital and conducted in accord-
ance with the provisions of the Declaration of Helsinki. This study is registered with ClinicalTrials.gov, number 
NCT03185221 (14/06/2017). All participating patients gave written informed consent.
Sample size. According to the reported reference13, 2-year TLF of Xience V is about 8.3%. Assuming the TLF 
of Xience V and Cordimax groups are both 8.5%, the non-inferiority threshold is 3%, the power is 80%, one-sided 
inspection level is 0.025, with the lost of 20%, the estimated cases are 2440:1220 (2:1 allocation).
Randomization. Patients were randomly assigned to receive either the Cordimax abluminal biodegradable 
polymer sirolimus-eluting stent (Rientech lnc., Shandong) or the Xience V durable polymer everolimus-eluting 
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stent (Abbott Vascular, Redwood City, CA, USA) in a 2:1 allocation. A site stratified block randomization with 
randomly varying block sizes of 4 and 6 was performed. Random assignment was performed by a statistician 
from Fudan University and random envelopes were assigned to each site. Sequences were concealed from patients 
and clinical staff until assignment.
Figure 2. Kaplan-Meier curves. Kaplan-Meier curves for the primary endpoint (A) and major adverse 
cardiovascular events (B), the primary safety endpoint (C), cardiac death (D), target-lesion revascularization 
(E), myocardial infarction (F), and stent thrombosis (G) at 3 years. Primary endpoint was a composite of cardiac 
death, target-vessel MI, or clinically indicated target-lesion revascularization (CI-TLR). The primary safety 
endpoint was a composite of death or myocardial infarction.
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Stents. The Cordimax sirolimus-eluting stent has a 316 L stainless steel platform coated on the abluminal 
surface with a biodegradable polylactide-co-polyglycolide copolymer (75:25 ratio) loaded with sirolimus10. The 
Cordimax stent was available in diameters of 2.5, 2.75, 3.0, 3.5 and 4.0 mm, and in lengths of 9, 12, 16, 18, 20, 23, 
28 and 33 mm. The Xience V everolimus-eluting stent has a L-605 cobalt-chromium platform with a conformal 
coating of a non-erodible polymer loaded with everolimus31. The Xience V stent was available in diameters of 
2.50, 2.75, 3.00, 3.5 and 4.00 mm, and in lengths of 8, 12, 15, 18, 23, and 28 mm.
Study protocol. The stents were implanted using standard techniques. Patients received 300 mg aspirin and 
300 mg clopidogrel at least 24 and six hours, respectively, before implantation, except for those who had been 
taking clopidogrel at 75 mg once daily for more than 72 hours. During the procedure, patients received unfrac-
tionated heparin at a dose of 100 IU/kg. Dual antiplatelet therapy with 100 mg aspirin and 75 mg clopidogrel once 
daily was continued for at least 1 year after stent implantation.
Clinical endpoints and follow-up. The primary endpoint was the composite rate of target-lesion failure 
(TLF), defined as cardiac death, target-vessel MI, or clinically indicated target-lesion revascularization (TLR), 
at 1 years of stent implantation. The primary safety endpoint was a composite of death or myocardial infarction 
(MI) at 3 years. Secondary clinical safety and efficacy endpoints included major adverse cardiovascular events 
(MACE, defined as nonfatal MI, all-cause mortality, or TLR), the individual components of the composite end-
points, and definite or probable stent thrombosis, within 3 years of stent implantation. Cardiac death was defined 
as any death due to an evident cardiac cause, death related to the procedure, unwitnessed death, or death from 
unknown causes. A target-lesion revascularization was deemed clinically indicated if the stenosis of the treated 
lesion was at least 50% of the lumen diameter within the stent or within a 5-mm border on either side of the stent. 
Stent thrombosis (ST) was defined as the composite of any stent thromboses (definite, or probable) according to 
Events Cordimax (n = 2460) Xience V (n = 1237) HR (95% CI) P value
TLF 28 (1.1%) 21 (1.7%) 0.67 (0.38–1.18) 0.16
All cause death 0 (0%) 2 (0.2%) — —
Cardiac death 0 (0%) 0 (0%) — —
MI 3 (0.2%) 1 (0.1%) 1.51 (0.16–14.49) 0.72
TLR (clinically driven) 25 (1.0%) 21 (1.7%) 1.01 (1.00–1.07) 0.08
Death or MI 3 (0.2%) 3 (0.2%) 0.50 (0.10–2.49) 0.39
MACE 28 (1.1%) 22 (1.8%) 0.64 (0.37–1.11) 0.11
ST 4 (0.2%) 2 (0.2%) 1.01 (0.18–5.48) 1.00
Table 3. Outcome differences between 1 year and 2 year. Values are n (%). *Relative risk (RR) and p values are 
from the chi-square test. MACE, Major Adverse Cardiovascular Event; MI, Myocardial Infarction; TLF, Target 
Lesion Failure; TLR, Target Lesion Revascularisation; and ST, Stent Thrombosis.
Events
Cordimax Xience V
RR (95% CI) P value(n = 2460) (n = 1237)
TLF 8 (0.3%) 17 (1.4%) 0.24 (0.10–0.55) <0.001
All cause death 2 (0.1%) 2 (0.2%) 0.50 (0.07–3.57) 0.48
Cardiac death 2 (0.1%) 2 (0.2%) 0.50 (0.07–3.57) 0.48
MI 0 (0%) 2 (0.2%) — —
TLR (clinically driven) 6 (0.2%) 14 (1.1%) 0.22 (0.08–0.56) <0.001
Death or MI 2 (0.1%) 4 (0.3%) 0.25 (0.05–1.37) 0.08
MACE 8 (0.3%) 17 (1.4%) 0.24 (0.10–0.55) <0.001
Table 4. Outcome differences between 2 year and 3 year. Values are n (%). *Relative risk (RR) and p values are 
from the chi-square test. MACE, Major Adverse Cardiovascular Event; MI, Myocardial Infarction; TLF, Target 
Lesion Failure; TLR, Target Lesion Revascularisation; and ST, Stent Thrombosis.
Stent Thrombosis
Cordimax Xience V
RR(95% CI) P value(n = 2460) (n = 1237)
Definite 10 (0.4%) 7 (0.6%) 0.50 (0.07–3.57) 0.61
Probable 0 (0%) 0 (0%) — —
Definite or Probable 10 (0.4%) 7 (0.6%) 0.50 (0.07–3.57) 0.61
Table 5. Stent Thrombosis at 3 years. Values are n (%). *Relative risk (RR) and p values are from the chi-square 
test.
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Academic Research Consortium (ARC) criteria32. Patients were systematically evaluated at 30 days, 6 months, 9 
months, 12 months, 2 years, and 3 years by follow-up phone calls and office visits.
Statistical analysis. The trial was powered to assess non-inferiority of the Cordimax sirolimus-eluting stent 
compared with the Xience V everolimus-eluting stent in terms of the primary endpoint (TLF) at 1 years. The 
published clinical trial results on the Xience V stent showed a TLF of 8.3% at 12 months33. On the basis of an 
assumed TLF of 8.5% in the Cordimax group, a prespecified non-inferiority margin of 0.03 (3%) with a one-sided 
type 1 error of 0.05, and a 2:1 (Cordimax/Xience V) ratio of patient allocation, the enrollment of 2034 patients in 
the Cordimax treatment arm and 1017 patients in the Xience V treatment arm was calculated to provide at least 
80% power to detect non-inferiority34. Assuming a 20% loss-to-follow-up rate, a total sample size of 3660 patients 
(2440 in the Cordimax arm and 1220 in the Xience V arm) were required.
Analysis was performed on an intent-to-treat basis. Categorical variables are reported as numbers and per-
centages of patients, and continuous variables as means and SD. Treatment group comparisons were performed 
using the chi-square test or Fisher’s exact test for categorical outcomes and the Wilcoxon rank-sum test for con-
tinuous outcomes. Relative risk (RR) with 95% confidence interval (CI) and p values are reported. Non-inferiority 
was defined as the upper 95% confidence limit for the difference between treatment groups no greater than prede-
termined non-inferiority margin of 0.03 (3%). Further, to identify independent risk factors of TLF, univariate and 
multivariable Cox proportional hazard regression analyses were performed. A two-sided P value of less than 0.05 
was considered to indicate statistical significance. Time-to-event analysis was performed using the Kaplan-Meier 
method, with treatment groups compared using the log-rank test. All analyses were performed with the SAS9.13 
software (SAS Institute Inc., Cary, NC, USA).
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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